Investigators evaluated children with acute lymphoblastic or acute myeloid leukemia to identify racial/ethnic and neighborhood disparities in acute kidney injury.

Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than those ...

Anthracycline and cytarabine chemotherapy has been the backbone of induction chemotherapy for AML for more than 50 years. Advances in our understanding of leukemia biology and the development of ...

The FDA on Wednesday approved a new all-oral regimen for newly diagnosed acute myeloid leukemia (AML) in patients ineligible ...

Developing effective immunotherapies for acute myeloid leukemia (AML) has long been hampered by a critical challenge: Therapy ...

Regulatory clearance creates an at-home, 28-day cycle option using oral decitabine/cedazuridine on days 1–5 plus venetoclax 400 mg daily after a ramp-up cycle. Efficacy signals in ASCERTAIN-V included ...

The choice of frontline therapy for a patient with chronic phase chronic myeloid leukemia (CP-CML) can have a profound effect on the long-term clinical outcome. Currently, five tyrosine kinase ...

A Phase I/II clinical trial shows that a stem cell transplant that removes CD33 from donor cells using CRISPR can prevent ...

It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...

Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.